Addex Therapeutics Partner Indivior’s GABAB Modulator Program Successfully Passes IND-Enabling Studies

Addex Therapeutics has announced that its partner, Indivior, has successfully completed the final preclinical stage of development for a GABAB positive allosteric modulator (PAM) program. The program has now advanced through IND-enabling studies, meaning it is ready to move into clinical trials. This progress is part of an ongoing research collaboration between Addex and Indivior, with a focus on developing treatments for substance use disorders. Indivior previously selected a GABAB PAM compound for this purpose. 

Tim Dyer, CEO of Addex, stated, “Our partner Indivior has made great progress with their GABAB PAM substance use disorders program, successfully completing the last preclinical safety and toxicity studies with the compound they selected from our research collaboration. This significant achievement demonstrates the quality of the compounds discovered by the Addex team. Our own GABAB PAM cough program is also advancing through preclinical studies and is scheduled to start IND enabling studies later this year.”

According to the agreement between the two companies, Addex is eligible to receive up to \$330 million in milestone payments tied to regulatory approvals, clinical progress, and commercial achievements. In addition, Addex will receive tiered royalties based on net sales, ranging from high single digits to low double digits. In parallel, Addex is also developing its own GABAB PAM compound independently for the treatment of chronic cough. This compound was selected under the same agreement and is progressing through its own development pathway.